This company currently has a 20 million dollar marketcap Canadian and has recently uplisted to the NASDAQ. They had a 9.6 million dollar public offering at a share price of 5.25 (USD) . source - ceo.ca/@thenewswire/...-uplisting-to-nasdaq
What's interesting is that the public offering is priced in USD however at the time of the public offering it and reverse split, it was traded below 5.1 Canadian dollars. Warrants are exercisable at 6.58 USD and it is currently trading at 5.6 CAD.
So where I am going with this is that there is a mispricing that is leading to the share to be trading at a significant discount then what is intended as if we were to convert 5.25 USD to CAD it's public offering in CAD should be 6.67$, yet it is currently trading at 5.6 a significant discount from it's public offering. based on their presentation from Dec they have a 19.28% insider ownership ( probably less after this dilution).
Based on this information, the cash they have accounts for half of their market cap! (potentially more if we assume the public offering is in USD). This really sucks for the long-term shareholders, but great for newcomers.
Looking at the product they have to offer seems innovative and disruptive. Their DehydraTECH is an innovative oral delivery system with the following features:
increases bio-absorption by up to 5x,
reduces time of onset from up to 1 – 2 hours to just minutes
masks unwanted tastes. and
can reduce unwanted side effects by enabling lower overall dosing.
Based on this, alone may have many uses in emergency situations if it's a time sensitive situation where delivery through intramuscular or intravenous is not practical.
www.youtube.com/watch?v=-N1krKKb...
The potential is incredible for this DehydraTECH as there are many drugs that may benefit from this innovative oral system, which can lead to many royalty opportunities for this company. They have a CBD and nicotine product and it has the potential to work with other antriviraldrugs
They also own 6 million shares of BEER.V at a price of 0.0829. If BEER.V behsin to make a run, then this ticker becomes even more of a bargain
In conclusion, I believe we have a heavily mispriced ticker with lots of cash in hand and the shares of BEER.V they own these current assets can easily surpass their own market cap! In addition to just uplisting to the nasdaq with a disruptive biotech tecnology with significant insider ownership this could be a 10 bagger.
presentation : d1io3yog0oux5.cloudf...esentation+FINAL.pdf
Technical look terrible, but its on the bottom of this long term channel so you're picking shares off the bottom of the channel. with the right catalyst in the future this can become an amazing investment!
What's interesting is that the public offering is priced in USD however at the time of the public offering it and reverse split, it was traded below 5.1 Canadian dollars. Warrants are exercisable at 6.58 USD and it is currently trading at 5.6 CAD.
So where I am going with this is that there is a mispricing that is leading to the share to be trading at a significant discount then what is intended as if we were to convert 5.25 USD to CAD it's public offering in CAD should be 6.67$, yet it is currently trading at 5.6 a significant discount from it's public offering. based on their presentation from Dec they have a 19.28% insider ownership ( probably less after this dilution).
Based on this information, the cash they have accounts for half of their market cap! (potentially more if we assume the public offering is in USD). This really sucks for the long-term shareholders, but great for newcomers.
Looking at the product they have to offer seems innovative and disruptive. Their DehydraTECH is an innovative oral delivery system with the following features:
increases bio-absorption by up to 5x,
reduces time of onset from up to 1 – 2 hours to just minutes
masks unwanted tastes. and
can reduce unwanted side effects by enabling lower overall dosing.
Based on this, alone may have many uses in emergency situations if it's a time sensitive situation where delivery through intramuscular or intravenous is not practical.
www.youtube.com/watch?v=-N1krKKb...
The potential is incredible for this DehydraTECH as there are many drugs that may benefit from this innovative oral system, which can lead to many royalty opportunities for this company. They have a CBD and nicotine product and it has the potential to work with other antriviraldrugs
They also own 6 million shares of BEER.V at a price of 0.0829. If BEER.V behsin to make a run, then this ticker becomes even more of a bargain
In conclusion, I believe we have a heavily mispriced ticker with lots of cash in hand and the shares of BEER.V they own these current assets can easily surpass their own market cap! In addition to just uplisting to the nasdaq with a disruptive biotech tecnology with significant insider ownership this could be a 10 bagger.
presentation : d1io3yog0oux5.cloudf...esentation+FINAL.pdf
Technical look terrible, but its on the bottom of this long term channel so you're picking shares off the bottom of the channel. with the right catalyst in the future this can become an amazing investment!
Comment:
at the bottom of a massive wedge, after a NASDAQ uplisting and raising of funds with bullish divergence forming on RSI and MACD. Could be the ultimate dip buy. Can be the ultimate Dip buy if this leads to a breakout of the wedge :)
Comment:
Comment:
Looks like a higher low is starting to set setting up nicely for a trend change, 11.9 will need to break to confirm the trend change, but honestly as an investor I think it will be an exciting year for LXX, many exciting things in the pipelines. a NR can send this thing flying. As this company makes more licensing deals with more companies and spread this highly scalable biotech across many fields they will get bigger and bigger.
Comment:
new video www.youtube.com/watch?v=WyWguZNO...